These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22878697)

  • 1. Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia.
    Kikuchi K; Nezu U; Inazumi K; Miyazaki T; Ono K; Orime K; Shirakawa J; Sato K; Koike H; Wakasugi T; Sato M; Kawakami C; Watanabe S; Yamakawa T; Terauchi Y
    J Atheroscler Thromb; 2012; 19(12):1093-101. PubMed ID: 22878697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load.
    Hiramitsu S; Miyagishima K; Ishii J; Matsui S; Naruse H; Shiino K; Kitagawa F; Ozaki Y
    J Cardiol; 2012 Nov; 60(5):395-400. PubMed ID: 22890076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia.
    Masuda D; Nakagawa-Toyama Y; Nakatani K; Inagaki M; Tsubakio-Yamamoto K; Sandoval JC; Ohama T; Nishida M; Ishigami M; Yamashita S
    Eur J Clin Invest; 2009 Aug; 39(8):689-98. PubMed ID: 19490064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes.
    Bozzetto L; Annuzzi G; Corte GD; Patti L; Cipriano P; Mangione A; Riccardi G; Rivellese AA
    Atherosclerosis; 2011 Jul; 217(1):142-8. PubMed ID: 21481394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia.
    Davis HR; Veltri EP
    J Atheroscler Thromb; 2007 Jun; 14(3):99-108. PubMed ID: 17587760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men.
    Matikainen N; Björnson E; Söderlund S; Borén C; Eliasson B; Pietiläinen KH; Bogl LH; Hakkarainen A; Lundbom N; Rivellese A; Riccardi G; Després JP; Alméras N; Holst JJ; Deacon CF; Borén J; Taskinen MR
    PLoS One; 2016; 11(1):e0145890. PubMed ID: 26752550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters.
    van Heek M; Austin TM; Farley C; Cook JA; Tetzloff GG; Davis HR
    Diabetes; 2001 Jun; 50(6):1330-5. PubMed ID: 11375333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid-lowering therapy does not affect the postprandial drop in high density lipoprotein-cholesterol (HDL-c) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial.
    Hajer GR; Dallinga-Thie GM; van Vark-van der Zee LC; Olijhoek JK; Visseren FL
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):870-7. PubMed ID: 18394022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic demonstration of intestinal NPC1L1 as a major determinant of hepatic cholesterol and blood atherogenic lipoprotein levels.
    Xie P; Zhu H; Jia L; Ma Y; Tang W; Wang Y; Xue B; Shi H; Yu L
    Atherosclerosis; 2014 Dec; 237(2):609-17. PubMed ID: 25463095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study of the effect of ezetimibe for postprandial hyperlipidemia.
    Xue EZ; Zhang MH; Liu CL
    Medicine (Baltimore); 2018 Nov; 97(46):e12960. PubMed ID: 30431570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ezetimibe increases intestinal expression of the LDL receptor gene in dyslipidaemic men with insulin resistance.
    Drouin-Chartier JP; Tremblay AJ; Lemelin V; Lépine MC; Lamarche B; Couture P
    Diabetes Obes Metab; 2016 Dec; 18(12):1226-1235. PubMed ID: 27460541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of gemigliptin, a dipeptidyl peptidase-4 inhibitor, on lipid metabolism and endotoxemia after a high-fat meal in patients with type 2 diabetes.
    Ahn CH; Kim EK; Min SH; Oh TJ; Cho YM
    Diabetes Obes Metab; 2017 Mar; 19(3):457-462. PubMed ID: 27868366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
    Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
    J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Niemann-Pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via decreased liver X receptor (LXR) activity in liver of obese male mice.
    Sugizaki T; Watanabe M; Horai Y; Kaneko-Iwasaki N; Arita E; Miyazaki T; Morimoto K; Honda A; Irie J; Itoh H
    Endocrinology; 2014 Aug; 155(8):2810-9. PubMed ID: 24773344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients.
    Hajer GR; Dallinga-Thie GM; van Vark-van der Zee LC; Visseren FL
    Atherosclerosis; 2009 Jan; 202(1):216-24. PubMed ID: 18533158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial.
    Olijhoek JK; Hajer GR; van der Graaf Y; Dallinga-Thie GM; Visseren FL
    J Cardiovasc Pharmacol; 2008 Aug; 52(2):145-50. PubMed ID: 18670365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia.
    Tremblay AJ; Lamarche B; Hogue JC; Couture P
    J Lipid Res; 2009 Jul; 50(7):1463-71. PubMed ID: 19305020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation.
    Dagli N; Yavuzkir M; Karaca I
    Inflammation; 2007 Dec; 30(6):230-5. PubMed ID: 17687635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients.
    González-Ortiz M; Martínez-Abundis E; Kam-Ramos AM; Hernández-Salazar E; Ramos-Zavala MG
    Cardiovasc Drugs Ther; 2006 Apr; 20(2):143-6. PubMed ID: 16761194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.